Evolution Of β-Tg Level In Diabetic Patients Undergoing Artificial Pancreas Treatment
Plasma β-thromboglobulin was measured at 0, 24 and 48 hours on 27 healthy subjects and 22 insulin-dependent diabetic patients undergoing a 48-hour artificial pancreas treatment (Biostator).Before treatment all the diabetic patients revealed β-TG levels which were significantly higher than those measured in healthy subjectsOn average, after 24 hours of blood glucose control, β-TG levels in the diabetic patients were not significantly reduced in comparison with the original β-TG levels. In contrast, after 48 hours of blood glucose control, plasma β-TG levels were significantly reduced.As β-TG is a platelet-specific protein, which is considered to be an indicator of the cell’s release reaction, these results suggest that short-term control of blood glucose levels is likely to influence platelet activation in diabetic patients.